Psyence Biomedical Ltd. PBM
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Psyence Biomedical Ltd. (PBM) is a healthcare company listed in the US with a market value of about $17M.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is future growth (0/5).
Key numbers: a P/E of 16.5.
About Psyence Biomedical
Psyence Biomedical is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 1 of the last 3 years in our data.
Score: 1.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- ROE above 15%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Net income | $1M | -$51M | -$3M |
| Free cash flow | -$4M | -$3M | — |
| EPS (diluted) | $0.19 | $-9.62 | $-0.60 |
| Net margin | — | — | — |
| ROIC | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Psyence Biomedical’s P/E ratio?
About 16.5, based on the last twelve months of diluted earnings per share.
Does Psyence Biomedical pay a dividend?
Not currently.
Is Psyence Biomedical a good stock to buy?
We do not give buy or sell advice. Psyence Biomedical scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.